31 results
8-K
EX-99.1
KURA
Kura Oncology Inc
2 May 24
Kura Oncology Reports First Quarter 2024
4:10pm
of ziftomenib in NPM1-mutant AML and working closely with FDA to bring this potentially innovative medicine to patients in urgent need of effective
8-K
EX-99.1
KURA
Kura Oncology Inc
3 Nov 22
Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million
7:16am
and look forward to their input as we work to deliver innovative science with the potential to benefit patients.”
“In addition, we are grateful … for the support of Hercules Capital, a company with a long history of investing in innovative biotechnology companies,” Dr. Wilson continued. “Together
424B5
KURA
Kura Oncology Inc
3 Nov 22
Prospectus supplement for primary offering
7:07am
into IND-enabling studies. We intend to direct this development candidate at innovative biology and larger disease indications in combination with other
424B5
g0n2qyjer8017qp
24 Feb 22
Prospectus supplement for primary offering
5:01pm
8-K
EX-99.1
0dldtjem d710v
24 Feb 22
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
4:07pm
8-K
EX-99.1
z5h5g0
4 Nov 21
Kura Oncology Reports Third Quarter 2021
4:13pm
8-K
EX-99.1
n7k8eg
5 Aug 21
Kura Oncology Reports Second Quarter 2021
4:11pm
8-K
EX-99.1
pxb0p4u0dpshmx 758
29 Jul 21
Kura Oncology Appoints Helen Collins, M.D. to Board of Directors
7:36am
8-K
EX-99.1
nx7wpabfxj9vg8yfz2
4 Jun 21
Kura Oncology Appoints Carol Schafer to
7:36am
8-K
EX-99.1
y4zu09ew10a1
6 May 21
Kura Oncology Reports First Quarter 2021
4:11pm